Tatli Ersan, Buturak Ali, Cakar Akif, Vatan Bulent M, Degirmencioglu Aleks, Agac Tarık M, Kilic Harun, Gunduz Huseyin, Akdemir Ramazan
Department of Cardiology, Sakarya University School of Medicine, Sakarya, Turkey.
Department of Cardiology, Acibadem University School of Medicine, Istanbul, Turkey.
J Interv Cardiol. 2015 Jun;28(3):305-12. doi: 10.1111/joic.12206. Epub 2015 May 20.
We aimed to present our experience regarding the unusual vascular complications and specific treatment strategies in patients who underwent transradial coronary procedure (TRC).
Transradial access provides lower vascular access site complication rates compared with transfemoral access. However, there is lack of data obtained from large study populations concerning the incidence and treatment strategies of hemorrhagic and vascular complications following a TRC in the literature.
10,324 patients (2,652 patients with percutaneous coronary intervention and 7,672 patients with a diagnostic transradial coronary angiography) who underwent a TRC from February 2010 to December 2014 were reviewed to identify cases of large hematoma, perforation, arteriovenous fistula, and pseudoaneurysm.
The observed incidence was 0.44% (45 patients) for all unusual vascular and hemorrhagic complications. Of these 45 patients; 32 patients (0.31%) presented with large hematoma (≥6 cm), 8 patients (0.08%) presented with perforation, 4 patients (0.04%) presented with arteriovenous fistula (AVF), and only 1 case (0.009%) presented with radial artery pseudoaneurysm. Forty-one of forty-five patients were managed with mechanical compression. Surgery was performed in only 3 cases; a patient with a brachial artery perforation leading to compartment syndrome, a patient with AVF resulting in limb ischemia, and a patient with radial artery pseudoaneurysm. A right internal mammarian artery perforation resulting in huge breast hematoma was treated via endovascular graft stent implantation.
Hemorrhagic and vascular complications are rarely seen during TRC. However, majority of these complications could be managed conservatively without a requirement for surgical reconstruction.
我们旨在介绍经桡动脉冠状动脉介入治疗(TRC)患者中不常见血管并发症及具体治疗策略的经验。
与经股动脉途径相比,经桡动脉途径的血管穿刺部位并发症发生率更低。然而,文献中缺乏来自大量研究人群关于TRC后出血和血管并发症发生率及治疗策略的数据。
回顾了2010年2月至2014年12月期间接受TRC的10324例患者(2652例接受经皮冠状动脉介入治疗,7672例接受诊断性经桡动脉冠状动脉造影),以确定大血肿、穿孔、动静脉瘘和假性动脉瘤的病例。
所有不常见血管和出血并发症的观察发生率为0.44%(45例患者)。在这45例患者中,32例(0.31%)出现大血肿(≥6 cm),8例(0.08%)出现穿孔,4例(0.04%)出现动静脉瘘(AVF),仅1例(0.009%)出现桡动脉假性动脉瘤。45例患者中有41例采用机械压迫治疗。仅3例患者接受了手术治疗,分别为1例因肱动脉穿孔导致骨筋膜室综合征的患者、1例因AVF导致肢体缺血的患者以及1例桡动脉假性动脉瘤患者。1例右乳内动脉穿孔导致巨大乳房血肿的患者通过血管内植入覆膜支架进行治疗。
TRC期间出血和血管并发症很少见。然而,这些并发症大多数可通过保守治疗,无需手术重建。